(Q40093356)

English

Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines

scientific article published on 14 August 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

head and neck squamous cell carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Jens Wagenblast

1

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Markus Hambek

2

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Mehran Baghi

3

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Wolfgang Gstöttner

4

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Klaus Strebhardt

5

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Hanns Ackermann

6

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Rainald Knecht

7

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

publication date

14 August 2007

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

134

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

323-330

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non–Small-Cell Lung Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical update: proteasome inhibitors in solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of proteasome inhibition in the treatment of lung cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib as an antitumor agent.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The proteasome: a suitable antineoplastic target

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Head and neck cancers: oral cavity, pharynx, and larynx

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Head and neck cancer: a global perspective on epidemiology and prognosis.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting the ubiquitin-proteasome pathway in cancer therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidemiological review of head and neck cancers in Karachi

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of taxanes for head and neck cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393

1 reference

https://pubmed.ncbi.nlm.nih.gov/17701215

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-007-0287-9

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40093356&oldid=2203392903"